Company Overview
Company Type: Public Company
Website: www.fsdpharma.com
Number of Employees: 17
Ticker: HUGE (CNSX)
Year Founded: 1998


Business Description
FSD Pharma Inc., a biotechnology company, operates in the pharmaceutical research and development business. Its lead candidate is FSD-201, an ultra-micronized palmitoylethanolamide for the treatment of inflammatory diseases. The company is also involved in the research and development of Lucid-Psych, a molecular compound identified for the treatment of mental health disorders; and Lucid-MS, a molecular compound identified for the treatment of neurodegenerative disorders. FSD Pharma Inc. was incorporated in 1998 and is headquartered in Toronto, Canada.

Financial Information (Currency: CAD, in mm) 
Market Capitalization
64.9
EBITDA
(34.2)
Total Enterprise Value
58.0
TEV/EBITDA
NM
EBIT
(40.2)
Cash & ST Invst.
7.8
P/Diluted EPS Before Extra
NM
Net Income
(39.3)
Total Debt
0.6
Price/Tang BV
4.7x
Capital Expenditure
(0.1)
Total Assets
29.3
Total Debt/EBITDA
NM




Currency in CAD in mm, LTM as of Jun-30-2023 TEV and Market Cap are calculated using a close price as of Oct-06-2023

Key Professionals
Name
Title
Durkacz, Anthony John
Founder & Executive Co-Chairman
Saeed, Zeeshan 
Founder, CEO, President & Executive Co-Chairman
Coyle, Nathan 
Chief Financial Officer
Carroll, Donal 
Chief Operating Officer
Adesso, Maryann 
Corporate Secretary
Kotra, Lakshmi P.
CEO of Lucid & Director
Mack, Randell 
President of FSD BioSciences
Cassidy, Kevin 
Vice President of Quality-Lucid
Chruscinski, Andrzej 
Vice President of Clinical & Scientific Affairs of Lucid

Key Board Members
Name
Title
Durkacz, Anthony John
Founder & Executive Co-Chairman
Saeed, Zeeshan 
Founder, CEO, President & Executive Co-Chairman
Kotra, Lakshmi P.
CEO of Lucid & Director
Kaushal, Nitin 
Independent Director
Allan, David G. P.
Member of Advisory Board
Bashir, Adnan 
Independent Director
Chow, Kwok 
Member of the Regulatory Advisory Board
Clarke, Hance 
Member of Research & Clinical Advisory Board
David, Gerald V.
Member of Advisory Board
Dunn, Shannon 
Member of Research & Clinical Advisory Board
Fish, Eleanor N.
Member of Research & Clinical Advisory Board
Gobburu, Joga 
Member of Regulatory Advisory Board


Primary Industry Classification
Pharmaceuticals


Primary Office Location
199 Bay Street Suite 4000 | Toronto, ON | M5L 1A9 | Canada
Phone: 416-854-8884   

Current and Pending Investors
Auxly Cannabis Group Inc. (TSX:XLY), First Republic Capital Corp, Asset Management Arm, Fortius Research and Trading Corp, Solarvest BioEnergy Inc. (TSXV:SVS)

Stock Quote and Chart (Currency: CAD)
Last  (Delayed)
 1.65
Market Cap (mm)
64.9
Open
 1.63
Shares Out. (mm)
39.4
Previous Close
 1.65
Float %
84.9%
Change on Day
0.02
Shares Sold Short (mm)
-
Change % on Day
1.2%
Dividend Yield %
-
Day High/Low
 1.67/ 1.63
Diluted EPS Excl. Extra Items
(1.01)
52 wk High/Low
 2.83/ 1.02
P/Diluted EPS Before Extra
NM
Volume (mm)
0.0020
Avg 3M Dly Vlm (mm)
0.03
Beta 5Y
1.17


 
Delayed Quote** | Last Updated on Oct-06-2023 12:00 AM (GMT-5)
CNSX:HUGE - Common Stock


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Current and Pending Subsidiaries / Investments
Company Name
Business Description
Geography
Primary Industry
LTM Total Rev.($mm)
LFQ Total Assets ($mm)
LFQ Total Debt ($mm)
Prismic Pharmaceuticals, Inc.
Prismic Pharmaceuticals, Inc., a pharmaceutical company, engages in developing and marketing non-addictive prescription drugs for the treatment of pain, inflammation, and neurological disorders. Prismic Pharmaceuticals, Inc. has a strategic partnership with Epitech Group SRL. The company was incorporated in 2011 and is based in Scottsdale, AZ. Prismic Pharmaceuticals, Inc. operates as a subsidiary of FSD Pharma Inc.

United States and Canada
Pharmaceuticals
-
-
-
620,000 Square Foot Indoor Plant in Ontario
As of November 9, 2017, 620,000 Square Foot Indoor Plant in Ontario was acquired by FSD Pharma Inc. 620,000 Square Foot Indoor Plant in Ontario comprises licensed facility for production of medical cannabis. The asset is located in Canada.

United States and Canada
Pharmaceuticals
-
-
-
Century Financial Capital Group Inc.
As of May 24, 2018, Century Financial Capital Group Inc. was acquired by FSD Pharma Inc. FSD Pharma Inc., a cannabis company, focuses on the hydroponic indoor cannabis production and processing activities in Canada. The company is headquartered in Ajax, Canada.

United States and Canada
Pharmaceuticals
0.00
2.00
0.00
2861435 Ontario Inc.
2861435 Ontario Inc., through its subsidiary, develops therapies to treat critical neurodegenerative diseases. The company was incorporated in 2021 and is based in Ontario, Canada. 2861435 Ontario Inc. operates as a subsidiary of FSD Pharma Inc.

United States and Canada
Biotechnology
-
-
-
Celly Nutrition Corp.
Celly Nutrition Corp. ws formerly known as 1319741 B.C. Ltd. and changed its name to Celly Nutrition Corp. in June 2023. The company was incorporated in 2021 and is based in Vancouver, Canada.

United States and Canada
-
-
-
-
FV Pharma Inc

United States and Canada
-
-
-
-
Huge Shops
Huge Shops retails cannabis products. Huge Shops has a strategic alliance with Chairmanâ€™s Brands. The company is based in Toronto, Canada.

United States and Canada
Other Specialty Retail
-
-
-


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Oct-05-2023
-
Spin-Off/Split-Off
Seller
Celly Nutrition Corp.

FSD Pharma Inc. (CNSX:HUGE)
-
Apr-12-2023
-
Spin-Off/Split-Off
Seller
Pubco

FSD Pharma Inc. (CNSX:HUGE)
-
Jan-13-2023
-
Buyback
Target
FSD Pharma Inc. (CNSX:HUGE)


-
Feb-25-2022
May-06-2022
Merger/Acquisition
Seller
Cobourg Facility in Cobourg, Ontario

FSD Pharma Inc. (CNSX:HUGE)
12.87
Dec-30-2021
-
Buyback
Target
FSD Pharma Inc. (CNSX:HUGE)


-
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Oct-05-2023
Spin-Off/Split-Off
FSD Pharma Inc. agreed to Spin-Off unknown stake of Celly Nutrition Corp.
Oct-04-2023
Lawsuits & Legal Issues
FSD Pharma Inc. Announces the Ontario Superior Court of Justice Has Dismissed the Motion to Set Aside the Arbitration Award to FSD Pharma Filed by Raza Bokhari
Sep-18-2023
Product-Related Announcements
FSD Pharma Announces Interim Results from First-In-Human Clinical Trial of Lucid-MS (Lucid-21-302) for Multiple Sclerosis
Aug-15-2023
Product-Related Announcements
FSD Pharma to Present Its Phase 1 Data on Lucid-MS At MSMilan 2023
Aug-02-2023
Client Announcements
FSD Pharma Inc. Signs Definitive Agreement to Launch UNBUZZD, a Revolutionary Rapid Alcohol Detoxification Drink

Competitors
7ACRES, 8423695 Canada Inc., 9037136 Canada Inc., AB Laboratories Inc., Abba Medix Corp., ABcann Medicinals Inc, Acreage Pharms Ltd., Agripharm Corp., Aurora Cannabis  Enterprises  Inc, Bedrocan Canada Inc., Bonify Medical Cannabis (BMC), Ltd, Broken Coast Cannabis Ltd., Canada's Island Garden Inc., Canna Farms Limited, CanniMed Ltd., CannTrust Inc., Decibel Cannabis Company Inc. (TSXV:DB), DelShen Therapeutics Corp., Delta 9 Cannabis Inc. (TSX:DN), Emblem Cannabis Corporation, Emerald Health Therapeutics, Inc., Entourage Health Corp. (TSXV:ENTG), Evergreen Medicinal Supply Inc., Experion Biotechnologies Inc., First Access Medical Inc, Green Relief Inc., GrenEx Pharms Inc., HEXO Corp., In the Zone Produce Ltd., INDIVA Inc., International Herbs Medical Marijuana Ltd., James E. Wagner Cultivation Corporation, Maricann Inc., MedReleaf Corp., Mettrum (Bennett North) Ltd, Mettrum Ltd, Natura Naturals Inc., Natural MedCo Ltd.,, OrganiGram Inc., Peace Naturals Project Inc., Prairie Plant Systems Inc., RockGarden Medicinals Inc., rTrees Producers Limited Inc., Scientus Pharma Inc., SNDL Inc. (NasdaqCM:SNDL), Solace Health Inc, Tantalus Labs, THC BioMed Ltd, Tilray Brands, Inc. (NasdaqGS:TLRY), Tilray Canada, Ltd., Tweed Farms Inc., Tweed Inc., Up Cannabis Inc., Whistler Medical Marijuana Corporation


Advisors
Most Recent Auditor
MNP LLP
Private Placement Advisors
First Republic Capital Corp.
Public Offering Advisors
Alliance Global Partners, Bennett Jones LLP, Brookline Capital Markets, LLC, MNP LLP, Paul, Weiss, Rifkind, Wharton & Garrison LLP


Most Recent Auditor
Meyers Norris Penny LLP - MNP LLP


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
The Economy Matters

Oct 02, 2023 03:08 AM
HUGE
The Economy Matters
Reports
8
GlobalData

Sep 21, 2023 05:45 AM
HUGE
FSD Pharma Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
56
GlobalData

Sep 15, 2023 01:06 AM
HUGE
FSD Pharma Inc (HUGE) - Pharmaceuticals and Healthcare Product Pipeline Summary
Reports
49
GlobalData

Sep 13, 2023 02:11 AM
HUGE
FSD Pharma Inc (HUGE) - Financial Analysis Review
Reports
154
Pechala's Reports

Aug 04, 2023 11:00 PM
HUGE
FSD PHARMA INC CLASS B SUBORDINATE-VOTIN (HUGE=US) - SHORT AND LONG TERM FORECASTS FOR ACTIVE TRADERS
Reports
2
GlobalData

Jun 28, 2023 04:13 AM
HUGE
FSD Pharma Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
47
GlobalData

Jun 09, 2023 05:04 AM
HUGE
FSD Pharma Inc (HUGE) - Financial Analysis Review
Reports
150
GlobalData

Jun 09, 2023 12:16 AM
HUGE
FSD Pharma Inc (HUGE) - Pharmaceuticals and Healthcare Product Pipeline Summary
Reports
49
Smart Insider Ltd.

Apr 12, 2023 01:03 AM
HUGE
FSD Pharma Inc: 1 director
Reporting Results*
1
GlobalData

Mar 13, 2023 04:22 AM
HUGE
FSD Pharma Inc (HUGE) - Financial Analysis Review
Reports
136


Ownership Summary

            Top Holders 
Holders by Type
Holder

Common Stock Equivalent Held

% of Total Shares Outstanding

Market Value (CAD in mm)

Position Date


Saeed, Zeeshan 

2,241,170

5.69

2.7

Apr-19-2023


Kotra BPHARM, Ph.D., Lakshmi P.

1,422,197

3.61

1.7

Mar-30-2023


Durkacz, Anthony John

1,017,122

2.58

1.2

Mar-30-2023


Carroll CPA, Donal 

973,268

2.47

1.2

Jul-28-2023


First Republic Capital Corp, Asset Management Arm

373,671

0.95

0.5

Mar-30-2023


Merrill Lynch & Co. Inc., Banking Investments

373,671

0.95

0.5

Mar-29-2022


AdvisorShares Investments, LLC

249,305

0.63

0.3

Jun-30-2023


Brennan Jr., F.A.C.S., FACS, M.D., Edward J.

112,920

0.29

0.1

Mar-29-2022


Fortius Research and Trading Corp

106,067

0.27

0.1

Mar-30-2023


Renaissance Technologies LLC

102,600

0.26

0.1

Jun-30-2023



 



Top Buyers
Buyers
Common Stock Equivalent Held
Change
Renaissance Technologies LLC
102,600
33,600
Susquehanna International Group, LLP, Asset Management Arm
57,465
22,570
Carroll CPA, Donal 
973,268
2,000
RBC Dominion Securities Inc., Asset Management Arm
1,036
369
Toronto-Dominion Bank, Securities Investments
76
7

Top Sellers
Sellers
Common Stock Equivalent Held
Change
Saeed, Zeeshan 
2,241,170
(90,503)
AdvisorShares Investments, LLC
249,305
(33,074)
Group One Trading LP, Asset Management Arm
0
(18,655)
Two Sigma Securities, LLC, Asset Management Arm
10,165
(12,099)
Citadel Advisors LLC
0
(2,643)


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
Date/Time
Headline
Source
Sep-14
FSD Pharma Announces Analyst Coverage Initiated by Singular Research
ENP Newswire


Company Coverage
This company is not on any Coverage List.

Products
LUCID-21-302 (Future), Lucid-MS


Upcoming Events
Date/Time
Type
Oct-20-2023
Estimated Earnings Release Date (S&P Global Derived)
* Future Events are subject to change.


Recent Major Filings

Key Filings
Filed On
Period Date
Company Name
Source
Form Type
Size
Oct-05-2023
-
FSD Pharma Inc. (CNSX:HUGE)
SEDAR
News Releases
147 KB
Oct-04-2023
-
FSD Pharma Inc. (CNSX:HUGE)
SEDAR
News Releases
206 KB
Sep-18-2023
-
FSD Pharma Inc. (CNSX:HUGE)
SEDAR
News Releases
205 KB
Sep-15-2023
-
FSD Pharma Inc. (CNSX:HUGE)
SEDAR
Documents Affecting the Rights of Security Holders
4 MB
Aug-31-2023
-
FSD Pharma Inc. (CNSX:HUGE)
SEDAR
Material Change Report
71 KB
Aug-28-2023
Aug-25-2023
FSD Pharma Inc. (CNSX:HUGE)
SEC
6-K
23 KB
Aug-25-2023
Aug-02-2023
FSD Pharma Inc. (CNSX:HUGE)
SEC
6-K
65 KB
Aug-25-2023
-
FSD Pharma Inc. (CNSX:HUGE)
SEDAR
News Releases
165 KB
Aug-04-2023
-
FSD Pharma Inc. (CNSX:HUGE)
SEDAR
Material Change Report
151 KB
Aug-04-2023
-
FSD Pharma Inc. (CNSX:HUGE)
SEDAR
Securities Acquisition Filings (Early Warning)
269 KB


Insider Trades
Holder Name
Trade Date Range
Security Type
Transacted Shares
Transaction Value Range (CAD)
Transaction Type
% Change
Source
Carroll CPA, Donal  (Chief Operating Officer)
Jul-28-2023
Class B Subordinate Voting Shares
2,000
3,020
Open Market Acquisition
0.21
Multiple
Saeed, Zeeshan  (Founder, CEO, President & Executive Co-Chairman)
Apr-17-2023 - Apr-19-2023
Class B Subordinate Voting Shares
59,000
132,239
Open Market Acquisition
2.70
Multiple
-
Apr-17-2023
Class B Subordinate Voting Shares
20,000
50,417
Open Market Acquisition
-
Exchange Announcement
-
Apr-19-2023
Class B Subordinate Voting Shares
39,000
81,821
Open Market Acquisition
-
Exchange Announcement
Saeed, Zeeshan  (Founder, CEO, President & Executive Co-Chairman)
Apr-13-2023
Class B Subordinate Voting Shares
23,000
59,352
Open Market Acquisition
1.07
Multiple
Saeed, Zeeshan  (Founder, CEO, President & Executive Co-Chairman)
Apr-11-2023 - Apr-12-2023
Class B Subordinate Voting Shares
51,600
140,687
Open Market Acquisition
2.45
Multiple
-
Apr-11-2023
Class B Subordinate Voting Shares
11,200
29,341
Open Market Acquisition
-
Exchange Announcement
-
Apr-12-2023
Class B Subordinate Voting Shares
40,400
111,346
Open Market Acquisition
-
Exchange Announcement
Saeed, Zeeshan  (Founder, CEO, President & Executive Co-Chairman)
Apr-10-2023
Class B Subordinate Voting Shares
30,100
74,729
Open Market Acquisition
1.45
Multiple
Excluding Automatic Transactions
Key Board Members Details
Name
Title
Phone
Fax
Email
Durkacz, Anthony John
Founder & Executive Co-Chairman
416-854-8884
-
Anthony@firstrepubliccapital.com
Saeed, Zeeshan 
Founder, CEO, President & Executive Co-Chairman
(416) 854-8888
-
zsaeed@fsdpharma.com
Kotra, Lakshmi P.
CEO of Lucid & Director
416-854-8884
-

Kaushal, Nitin 
Independent Director
416-854-8884
-

Allan, David G. P.
Member of Advisory Board
416-854-8884
-

Bashir, Adnan 
Independent Director
416-854-8884
-

Chow, Kwok 
Member of the Regulatory Advisory Board
416-854-8884
-

Clarke, Hance 
Member of Research & Clinical Advisory Board
416-854-8884
-

David, Gerald V.
Member of Advisory Board
416-854-8884
-

Dunn, Shannon 
Member of Research & Clinical Advisory Board
416-854-8884
-

Fish, Eleanor N.
Member of Research & Clinical Advisory Board
416-854-8884
-

Gobburu, Joga 
Member of Regulatory Advisory Board
416-854-8884
-

* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Durkacz, Anthony John
Founder & Executive Co-Chairman
416-854-8884
-
Anthony@firstrepubliccapital.com
Saeed, Zeeshan 
Founder, CEO, President & Executive Co-Chairman
(416) 854-8888
-
zsaeed@fsdpharma.com
Coyle, Nathan 
Chief Financial Officer
416-854-8884
-
ncoyle@fsdpharma.com
Carroll, Donal 
Chief Operating Officer
416-854-8884
-

Adesso, Maryann 
Corporate Secretary
416-854-8884
-

Kotra, Lakshmi P.
CEO of Lucid & Director
416-854-8884
-

Mack, Randell 
President of FSD BioSciences
416-854-8884
-

Cassidy, Kevin 
Vice President of Quality-Lucid
416-854-8884
-

Chruscinski, Andrzej 
Vice President of Clinical & Scientific Affairs of Lucid
416-854-8884
-

* denotes that the relationship is proprietary

Historical Equity Pricing Data supplied by Interactive Data Pricing and Reference Data LLC 
S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENTâ€™S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligenceâ€™s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 

**Intraday Quotes are delayed by at least 20 minutes.
